A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)
Recruiting now · Phase 1
Conditions studied: Rheumatoid Arthritis (RA)
In brief
This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.
Key facts
- Study ID
- NCT07564154
- Run by
- Kali Therapeutics, Inc.
- People needed
- 27
- Starts
- 2026-07-13
- Expected to finish
- 2028-07-01
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Kali Therapeutics Trial Site — Bayswater, Victoria, Australia (enrolling)
- Kali Therapeutics Trial Site — Auckland, NZ, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.